Recent Stage IV Melanoma News

Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around... Continue Reading


Epacadostat Plus Keytruda® Appears Effective in Melanoma

(October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form... Continue Reading


Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

(September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory... Continue Reading


3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

(July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading


Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

(December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which... Continue Reading


Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma

(June 29, 2015)

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual... Continue Reading


Melanoma Drug T-VEC Receives Recommendation for FDA Approval

(May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical... Continue Reading


Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma

(April 20, 2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings... Continue Reading


Coffee May Decrease Risk of Melanoma Skin Cancer

(February 2, 2015)

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been... Continue Reading


FDA Approves Nivolumab for Advanced Melanoma

(December 23, 2014)

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients... Continue Reading


Next Page »